Search Results - "Riviere, Marie‐Emmanuelle"

The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease by Lopez Lopez, Cristina, Tariot, Pierre N., Caputo, Angelika, Langbaum, Jessica B., Liu, Fonda, Riviere, Marie-Emmanuelle, Langlois, Carolyn, Rouzade-Dominguez, Marie-Laure, Zalesak, Martin, Hendrix, Suzanne, Thomas, Ronald G., Viglietta, Vissia, Lenz, Rob, Ryan, J. Michael, Graf, Ana, Reiman, Eric M.

“…Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta (Aβ) species and tau pathology, begins decades before the onset of cognitive…”
Get full text

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study by Vandenberghe, Rik, Riviere, Marie-Emmanuelle, Caputo, Angelika, Sovago, Judit, Maguire, R. Paul, Farlow, Martin, Marotta, Giovanni, Sanchez-Valle, Raquel, Scheltens, Philip, Ryan, J. Michael, Graf, Ana

“…Abstract Introduction This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without…”
Get full text

Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes by Riviere, Marie‐Emmanuelle, Langbaum, Jessica B., Turner, R. Scott, Rinne, Juha O., Sui, Yihan, Cazorla, Pilar, Ricart, Javier, Meneses, Kathleen, Caputo, Angelika, Tariot, Pierre N., Reiman, Eric M., Graf, Ana

“…INTRODUCTION Alzheimer's Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE‐1 inhibitor…”
Get full text

The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease by Langbaum, Jessica B, Ellison, Noel N, Caputo, Angelika, Thomas, Ronald G, Langlois, Carolyn, Riviere, Marie-Emmanuelle, Graf, Ana, Lopez Lopez, Cristina, Reiman, Eric M, Tariot, Pierre N, Hendrix, Suzanne B

“…There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer's disease (AD) treatment…”
Get full text

Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer's disease by Caputo, Angelika, Racine, Amy, Paule, Ines, Tariot, Pierre N, Langbaum, Jessica B, Coello, Neva, Riviere, Marie-Emmanuelle, Ryan, J Michael, Lopez, Cristina Lopez, Graf, Ana

“…There is a critical need for novel primary endpoints designed to detect early and subtle changes in cognition in clinical trials targeting the asymptomatic…”
Get full text

Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials by Langlois, Carolyn M., Bradbury, Angela, Wood, Elisabeth M., Roberts, J. Scott, Kim, Scott Y.H., Riviere, Marie-Emmanuelle, Liu, Fonda, Reiman, Eric M., Tariot, Pierre N., Karlawish, Jason, Langbaum, Jessica B.

“…As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to…”
Get full text

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease by Farlow, Martin R, Andreasen, Niels, Riviere, Marie-Emmanuelle, Vostiar, Igor, Vitaliti, Alessandra, Sovago, Judit, Caputo, Angelika, Winblad, Bengt, Graf, Ana

“…CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106 first-in-human study…”
Get full text

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies by Tariot, Pierre N., Riviere, Marie‐Emmanuelle, Salloway, Stephen, Burns, Jeffrey M., Snaedal, Jón G., Borowsky, Beth, Lopez, Cristina Lopez, Liu, Fonda, Rouzade‐Dominguez, Marie‐Laure, Cazorla, Pilar, Mousseau, Marie‐Catherine, Arkuszewski, Michal, Ricart, Javier, Viglietta, Vissia, Sui, Yihan, Caputo, Angelika, Langbaum, Jessica B., Reiman, Eric M., Graf, Ana

“…INTRODUCTION The Alzheimer's Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer's disease (AD) prevention…”
Get full text

API generation program: Active immunotherapy CAD106 slows amyloid deposition in cognitively unimpaired APOE4 homozygotes by Riviere, Marie‐Emmanuelle, Turner, Raymond Scott, Sui, Yihan, Laurent, Nathalie, Langbaum, Jessica B., Cazorla, Pilar, Ricart, Javier, Seneca, Nicholas, Caputo, Angelika, Reiman, Eric M., Tariot, Pierre N., Graf, Ana

“…Background The Alzheimer’s Prevention Initiative (API) Generation Study 1 (NCT0256551) evaluated CAD106, an active immunotherapy against Aβ, in delaying the…”
Get full text

Active immunotherapy options for Alzheimer's disease by Winblad, Bengt, Graf, Ana, Riviere, Marie-Emmanuelle, Andreasen, Niels, Ryan, J Michael

“…Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is…”
Get full text

Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy by Pålhagen, Sven, Canger, Raffaele, Henriksen, Olaf, van Parys, Johan A., Rivière, Marie-Emmanuelle, Karolchyk, Mary Ann

“…Objective: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients…”
Get full text

The Alzheimer Prevention Initiative Generation Program: Evaluation of CNP520 in Preclinical Alzheimer’s Disease (P4.1-005) by Borowsky, Beth, Lopez, Cristina Lopez, Tariot, Pierre, Caputo, Angelika, Liu, Fonda, Riviere, Marie-Emmanuelle, Rouzade-Dominguez, Marie-Laure, Thomas, Ronald, Langbaum, Jessica, Viglietta, Vissia, Reiman, Eric, Graf, Ana

“…Abstract only…”
Get full text

The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2 by Rouzade‐Dominguez, Marie‐Laure, Riviere, Marie‐Emmanuelle, Borowsky, Beth, Liu, Fonda, Cazorla, Pilar, Quinn, Matt, Seneca, Nicholas, Neumann, Ulf, Eichenlaub, Udo, Chien, Yuchen, Viglietta, Vissia, Reiman, Eric M., Sui, Yihan, Caputo, Angelika, Graf, Ana

“…Background API Generation Program evaluated the effectiveness of the BACE1 inhibitor umibecestat and the active immunotherapy CAD106 in delaying the onset of…”
Get full text

The Alzheimer’s prevention initiative Generation program: A global perspective on best practices for site support and engagement to accelerate participant recruitment: Clinical trial design and implementation by Walsh, Trisha L., Riviere, Marie‐Emmanuelle, Tariot, Pierre N., Alred, Melody, Doak, Karen, Liu, Fonda, Ricart, Javier, Scholten, Ingo, Arbuckle, Julian, Quinn, Matt, Duff, Laurie, Smith, Molly, Graf, Ana, Langbaum, Jessica B.

Get full text

Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out: Alzheimer’s Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up by Graf, Ana, Riviere, Marie‐Emmanuelle, Liu, Fonda, Rouzade‐Dominguez, Marie‐Laure, Cazorla, Pilar, Quinn, Matt, Arkuszewski, Michal, Ricart, Javier, Langbaum, Jessica B., Piccard, Hernan, Sui, Yihan, Quarg, Peter, Caputo, Angelika, Reiman, Eric M., Tariot, Pierre N.

Get full text

The Alzheimer’s prevention initiative Generation program: A global perspective on best practices for site support and engagement to accelerate participant recruitment by Walsh, Trisha L., Riviere, Marie‐Emmanuelle, Tariot, Pierre N., Alred, Melody, Doak, Karen, Liu, Fonda, Ricart, Javier, Scholten, Ingo, Arbuckle, Julian, Quinn, Matt, Duff, Laurie, Smith, Molly, Graf, Ana, Langbaum, Jessica B.

“…Background The API Generation Program consists of two trials: Generation Studies 1 and 2. Generation Study 1 enrolled cognitively unimpaired APOE4 homozygotes…”
Get full text

Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out by Graf, Ana, Riviere, Marie‐Emmanuelle, Liu, Fonda, Rouzade‐Dominguez, Marie‐Laure, Cazorla, Pilar, Quinn, Matt, Arkuszewski, Michal, Ricart, Javier, Langbaum, Jessica B., Piccard, Hernan, Sui, Yihan, Quarg, Peter, Caputo, Angelika, Reiman, Eric M., Tariot, Pierre N.

“…Background Recruitment in the API Generation program and treatment with umibecestat were terminated in July 2019 after detection of an early signal of mild…”
Get full text

The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2: Alzheimer’s Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up by Tariot, Pierre N., Borowsky, Beth, Liu, Fonda, Riviere, Marie‐Emmanuelle, Rouzade‐Dominguez, Marie‐Laure, Cazorla, Pilar, Quinn, Matt, Ricart, Javier, Langbaum, Jessica B., Viglietta, Vissia, Sui, Yihan, Caputo, Angelika, Reiman, Eric M., Graf, Ana

Get full text

The Generation program: Baseline characteristics of cognitively unimpaired APOE4 carriers recruited for Generation study 1 and Generation study 2 by Tariot, Pierre N., Borowsky, Beth, Liu, Fonda, Riviere, Marie‐Emmanuelle, Rouzade‐Dominguez, Marie‐Laure, Cazorla, Pilar, Quinn, Matt, Ricart, Javier, Langbaum, Jessica B., Viglietta, Vissia, Sui, Yihan, Caputo, Angelika, Reiman, Eric M., Graf, Ana

“…Background The Alzheimer Prevention Initiative (API) Generation Program evaluated the effectiveness of the BACE1 inhibitor, umibecestat, and the active…”
Get full text

The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2: Alzheimer’s Prevention Initiative (API) Generation program: Baseline characteristics and umibecestat results during treatment and follow‐up by Rouzade‐Dominguez, Marie‐Laure, Riviere, Marie‐Emmanuelle, Borowsky, Beth, Liu, Fonda, Cazorla, Pilar, Quinn, Matt, Seneca, Nicholas, Neumann, Ulf, Eichenlaub, Udo, Chien, Yuchen, Viglietta, Vissia, Reiman, Eric M., Sui, Yihan, Caputo, Angelika, Graf, Ana

Get full text